BTIG Maintains Buy on Mustang Bio, Raises Price Target to $20
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Justin Zelin maintains a Buy rating on Mustang Bio (NASDAQ:MBIO) and raises the price target from $4 to $20.
June 16, 2023 | 3:25 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mustang Bio's price target has been raised from $4 to $20 by BTIG analyst Justin Zelin, who maintains a Buy rating on the stock.
The price target increase from $4 to $20 by BTIG analyst Justin Zelin indicates a strong positive outlook for Mustang Bio. This news is likely to have a positive impact on the stock price in the short term as it reflects the analyst's confidence in the company's potential growth and performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100